Colombani J
Immunology and Histocompatibility Laboratory, Hôpital Saint-Louis, Paris, France.
Tissue Antigens. 1990 Mar;35(3):103-13. doi: 10.1111/j.1399-0039.1990.tb01765.x.
Amino acid sequences and structural data on HLA class I molecules are now available, making possible a comparison of the serological and structural definitions of allelic series. 1) A hierarchy of differences between molecules is observed. Certain molecules show a low level of differences (1.2% of amino acids) and represent variants of original molecules. Other molecules are recombinants derived from two parent molecules (2.5% difference). Original molecules from an allelic series have a higher level of difference (7.6%). Maximum differences (13.5%) are observed between products from different loci. Serologically related specificities (cross-reacting groups) show a relatively low level of difference (6.4%). 2) In most specificities an exclusive residue can be considered as responsible for the formation of a serologically recognized determinant. Certain specificities do not have an exclusive residue; they can then be characterized either by a unique determinant made by the association of several non-exclusive residues, or by an unique association of several non-exclusive (shared) determinants. There is a significant correlation between the absence of an exclusive residue and the absence of monoclonal antibodies recognizing certain specificities. This suggests two kinds of definition of serological specificities, either by a single exclusive determinant (monotopic recognition) or by several shared determinants (polytopic recognition). Private and public specificities are recognized at the structural level. T-cell receptor (TCR) recognizes either a xenogeneic peptide in the context of self HLA molecules (restricted CTL [Cytotoxic T Lymphocyte]), or allogeneic HLA molecules. Determinants recognized by CTL (restricted or allogeneic) on HLA molecules have been identified. It is not possible to ascertain whether determinants recognized by antibodies and TCRs are identical, but they are probably very similar. 3) HLA class I molecule is made of 75% conserved residues (mostly in the alpha 3 and beta 2-m domains) and of 25% variable residues (mostly in the alpha 1 + alpha 2 domains). Conserved residues maintain the general shape of the molecule, its outward orientation on the cell membrane, its association with T cells CD8 molecule, and the structure of the peptide binding site, a groove at the top of molecule. Variable residues are responsible for the capacity of each molecule to bind and to present a large number of different peptides to the TCR. Each molecule carries several (3-10?) variable sites; certain are localized into the groove and are recognition sites while others, more exposed on the surface of the molecule, are sites recognized by TCRs and antibodies. Both conserved and variable regions are necessary to the function of the HLA molecule.
现已获得HLA I类分子的氨基酸序列和结构数据,从而能够比较等位基因系列的血清学定义和结构定义。1)观察到分子之间存在差异层次。某些分子显示出低水平的差异(氨基酸的1.2%),代表原始分子的变体。其他分子是源自两个亲本分子的重组体(差异为2.5%)。等位基因系列的原始分子具有更高水平的差异(7.6%)。在来自不同基因座的产物之间观察到最大差异(13.5%)。血清学相关特异性(交叉反应组)显示出相对较低水平的差异(6.4%)。2)在大多数特异性中,一个排他性残基可被视为负责形成血清学可识别的决定簇。某些特异性没有排他性残基;它们可以通过由几个非排他性残基的组合形成的独特决定簇来表征,或者通过几个非排他性(共享)决定簇的独特组合来表征。排他性残基的缺失与识别某些特异性的单克隆抗体的缺失之间存在显著相关性。这表明血清学特异性有两种定义方式,要么通过单个排他性决定簇(单表位识别),要么通过几个共享决定簇(多表位识别)。个体特异性和公共特异性在结构水平上得到识别。T细胞受体(TCR)识别自身HLA分子背景下的异种肽(限制性细胞毒性T淋巴细胞[CTL])或同种异体HLA分子。已经鉴定了CTL(限制性或同种异体)在HLA分子上识别的决定簇。无法确定抗体和TCR识别的决定簇是否相同,但它们可能非常相似。3)HLA I类分子由75%的保守残基(主要在α3和β2-m结构域)和25%的可变残基(主要在α1 + α2结构域)组成。保守残基维持分子的总体形状、其在细胞膜上的外向取向、其与T细胞CD8分子的结合以及肽结合位点的结构,肽结合位点是分子顶部的一个凹槽。可变残基负责每个分子结合并向TCR呈递大量不同肽的能力。每个分子携带几个(3 - 10个?)可变位点;某些位于凹槽内是识别位点,而其他更多暴露在分子表面的是被TCR和抗体识别的位点。保守区和可变区对于HLA分子的功能都是必需的。